Arch Cardiovasc Dis May 2025 PMID 40011110

Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial.

Romain Didier, Gilles Lemesle, Gilles Montalescot, P H Gabriel Steg, Eric Vicaut, Dominique Mottier, Christophe Bauters, Philippe Mabo, Tabassome Simon, Claire Bouleti, Stephane Andrieu, Denis Angoulvant, Gerald Vanzetto, Mathieu Kerneis, Guillaume Cayla

Full text PDF Download social card

Mentions

Peak: 12 in Sep 2025

across 2 sources since Aug 2025

Extended reach

149,183

potential audience

Total likes

Video views

Mentions per month

Aug 2025 – Nov 2025

Where it's discussed

X / Twitter18 posts
YouTube2 videos

AI synopsis

What people are saying

The overall tone suggests cautious optimism about the AQUATIC trial, with posts discussing its potential to shape treatment choices using words like 'important' and 'promising.' The references to the trial's design, such as 'double-blind' and 'randomized,' show an interest in the scientific rigor, while some posts emphasize the practical importance of balancing bleeding risks and heart attack prevention, highlighting its clinical impact.

AgreementModerate agreement

Most discussions acknowledge the importance of the study and its potential to influence treatment decisions, reflected in positive or neutral opinions.

InterestModerate interest

Participants show a moderate level of curiosity about the trial, as evidenced by their engagement with the research design and implications.

EngagementModerate engagement

Comments range from brief acknowledgments to more detailed reflections on the trial's methodology and significance, indicating moderate engagement.

ImpactNeutral impact

While the study is seen as relevant to clinical practice, opinions vary on its immediate impact; some see it as promising, others note the need for results.

Abstract in brief

The AQUATIC study is a clinical trial designed to determine whether patients with stable coronary artery disease who have stents and need long-term blood thinners should continue taking aspirin or stop it to reduce bleeding without increasing the risk of heart problems.
It involves 2000 high-risk patients who are randomly assigned to receive either blood thinners plus aspirin or blood thinners plus a placebo, with the goal of seeing which approach better prevents serious heart and blood vessel events while minimizing bleeding.
The main focus is to find the best balance between preventing severe cardiovascular issues like heart attacks and strokes, and avoiding dangerous bleeding, to guide long-term treatment decisions for these patients.

Read the full abstract

All mentions

Extended Anticoagulation Treatment for Provoked VTE Insights from HIPRO Study

Prof. Bikdeli and Prof. Didier discuss the HIPRO study on extended treatment of provoked venous thromboembolism, presented at the 2025 European Society of Cardiology meeting. The study compares rivaroxaban monotherapy…

MARKUS at HOMe · Nov 18, 2025 0 views

Optimizing Antithrombotic Therapy in Cardiovascular Patients with Antiplatelet and Anticoagulant Use

Prof Romain Didier and Prof Behnood Bikdeli discuss the AQUATIC study on antiplatelet drugs in patients with chronic coronary syndrome receiving oral anticoagulation, highlighting recent findings on therapy optimization…

MARKUS at HOMe · Nov 13, 2025 0 views

SawdustAndStars

@SuisDaria · X

RT @PCRonline: #ESCCongress

Sep 9, 2025 · 11 shares · 478 followers View post →

Ronnie Lassiaille

@RonnieLass · X

RT @PCRonline: #ESCCongress

Sep 7, 2025 · 11 shares · 1,037 followers View post →

DrThomasCuisset

@CuissetDr · X

RT @PCRonline: #ESCCongress

Sep 3, 2025 · 11 shares · 1,794 followers View post →

Bartosz Hudzik MD PhD FESC FACC

@BartoszHudzik · X

RT @PCRonline: #ESCCongress

Sep 1, 2025 · 11 shares · 1,423 followers View post →

Aaysha Cader

@aayshacader · X

RT @PCRonline: #ESCCongress

Sep 1, 2025 · 11 shares · 9,105 followers View post →

Hany Ragy

@Hragy · X

RT @PCRonline: #ESCCongress

Sep 1, 2025 · 11 shares · 80,668 followers View post →

EOLO MORANDI JR.

@eolojr · X

RT @PCRonline: #ESCCongress

Sep 1, 2025 · 11 shares · 546 followers View post →

JorgeEdoChava75

@QicenoJorge · X

RT @PCRonline: #ESCCongress

Sep 1, 2025 · 11 shares · 1,004 followers View post →

Salvatore Brugaletta

@sbrugaletta · X

RT @PCRonline: #ESCCongress

Sep 1, 2025 · 11 shares · 13,758 followers View post →

Samuel Lewis

@saminnomedai · X

RT @PCRonline: #ESCCongress

Sep 1, 2025 · 11 shares · 29 followers View post →

Alessandro Sticchi

@Sticchi_Alex · X

RT @PCRonline: #ESCCongress

Sep 1, 2025 · 11 shares · 3,962 followers View post →

PCRonline

@PCRonline · X

#ESCCongress

Sep 1, 2025 · 17 likes · 11 shares · 27,895 followers View post →